In the pathway to response: Is aflibercept an optimal treatment for RASwt mCRC patients after progression to 1st line containing anti-EGFR?

Velasco, Eladio; González-Flores, Encarnación; Martel, Ignacio Juez; Alonso, Vicente; Gómez, Patricia; Lago, Nieves Martínez; López, Carlos; Romero, Jose Manuel Cabrera; Aguilera, M.J. Safont; Ruiz-Casado, Ana; Fernández, Mercedes Salgado; Astorga, Beatriz Gonzalez; Escudero, P.; Herrero, F. Rivera; Pijaume, Carles Pericay; Vera, Ruth

doi:10.1093/annonc/mdy281.026

The platform will undergo maintenance on Sep 14 at about 7:45 AM EST and will be unavailable for approximately 2 hours.

Annals of Oncology

2018

DOI: 10.1093/annonc/mdy281.026

|View full text |Cite

In the pathway to response: Is aflibercept an optimal treatment for RASwt mCRC patients after progression to 1st line containing anti-EGFR?

Eladio Velasco

Encarnación González-Flores

Ignacio Juez Martel

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2019

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

In the pathway to response: Is aflibercept an optimal treatment for RASwt mCRC patients after progression to 1st line containing anti-EGFR?

Cited by 1 publication

References 0 publications

The role of PIGF blockade in the treatment of colorectal cancer: overcoming the pitfalls

The role of PIGF blockade in the treatment of colorectal cancer: overcoming the pitfalls

Contact Info

Product

Resources

About